In the lead-up to World Duchenne Awareness Day (Sunday, 7 September), we’re pleased to announce the completion of our first assessment of an externally developed clinical guideline – marking a ...

Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

This guideline has been updated and replaced by NICE guideline NG123.

There are commercial access agreements for enfortumab vedotin and pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor ...

This guidance has been updated and replaced by NICE technology appraisal guidance TA798 ...

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...

This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services. This ...

This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic ...

Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine Technology appraisal guidance TA53 Published: 06 December 2002 Last updated: 01 August 2015 ...

We provide access to a range of journals, databases and other evidence-based resources for health and social care staff in England. You'll need an NHS OpenAthens account to access most of these ...

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous ...